RT Journal Article
SR Electronic
T1 Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.09.21267566
DO 10.1101/2021.12.09.21267566
A1 Song, Joon-Young
A1 Kim, Yeon-Sook
A1 Eom, Joong-Sik
A1 Kim, Jin-Yong
A1 Lee, Jin-Soo
A1 Lee, Jacob
A1 Choi, Won-Suk
A1 Heo, Jung-Yeon
A1 Sohn, Jang-Wook
A1 Lee, Ki-Deok
A1 Cho, Donghui
A1 Cho, Ilyoung
A1 Kim, Woo-Joo
YR 2021
UL http://medrxiv.org/content/early/2021/12/14/2021.12.09.21267566.abstract
AB Background Clevudine, an antiviral drug for chronic hepatitis B virus infection, is expected to inhibit the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Therefore, we conducted a prospective, single-blind, proof of concept clinical study to examine the antiviral efficacy and safety of clevudine compared to placebo in Korean corona virus disease 19 (COVID-19) patients with moderate severity.Methods Adults with confirmed SARS-CoV-2 infection and symptom onset within 7 days were randomized 2:1 to 120 mg clevudine or placebo to receive one of treatments orally once-daily for 14 days. Antiviral efficacy outcomes were the proportion of patients with real-time reverse transcription polymerase chain reaction (RT-PCR) negative result for SARS-CoV-2 infection and cycle threshold (Ct) value changes from baseline. Clinical efficacy outcomes included proportion of patients who showed improvement in lung involvement by imaging tests, proportion of patients with normal body temperature, proportion of patients with normal oxygen saturation, and the changes in C-reactive protein (CRP) from baseline. Safety outcomes included changes in clinical laboratory tests, vital signs measurement, and physical examination from baseline, and incidence of adverse events.Results The proportion of patients with real-time RT-PCR negative test and Ct value changes showed no significant difference between clevudine group and placebo group. The changes in Ct value from baseline were significantly greater in clevudine group compared to placebo group in patients with hypertension, and patients who underwent randomization during the first 5 and 7 days after the onset of symptoms. All clinical efficacy outcomes had no significant difference between clevudine group and placebo group. Clevudine was well tolerated and there was no significant difference in safety profile between two treatment groups.Conclusions This is the first clinical study to compare the antiviral efficacy and safety of clevudine to placebo in Korean COVID-19 patients with moderate severity. The study has demonstrated a possible favorable outcome for the reduction of SARS-CoV-2 replication, with acceptable safety profile, when COVID-19 patients were treated with clevudine. Further large-scale clinical studies, preferably with various clinical endpoints and virus titer evaluation, are required to better understand the effectiveness of using clevudine in COVID-19 treatment. Considering recent trend in clinical development for antiviral drugs, we need to design a clinical study aiming for reducing clinical risk of COVID-19 in mild to moderate patients with at least one risk factor for serious illness.Competing Interest StatementGrant funding for research but no other competing interestClinical TrialNCT04347915Funding StatementThis study was funded by Bukwang Pharm. Co. Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Korea University Guro Hospital gave ethical approval for this work. IRB of Chungnam National University Hospital gave ethical approval for this work. IRB of Gachon University Gil Medical Center gave ethical approval for this work. IRB of Incheon Medical Center gave ethical approval for this work. IRB of Inha University Hospital gave ethical approval for this work. IRB of Hallym University Medical Center gave ethical approval for this work IRB of Korea University Ansan Hospital gave ethical approval for this work. IRB of Ajou University Medical Center gave ethical approval for this work IRB of Korea University Anam Hospital gave ethical approval for this work. IRB of Myongji Hospital gave ethical approval for this work. IRB of Seoul Medical Center gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.